JP2019532105A - 角結膜のホメオスタシスを確立、回復及び維持するための方法 - Google Patents

角結膜のホメオスタシスを確立、回復及び維持するための方法 Download PDF

Info

Publication number
JP2019532105A
JP2019532105A JP2019541893A JP2019541893A JP2019532105A JP 2019532105 A JP2019532105 A JP 2019532105A JP 2019541893 A JP2019541893 A JP 2019541893A JP 2019541893 A JP2019541893 A JP 2019541893A JP 2019532105 A JP2019532105 A JP 2019532105A
Authority
JP
Japan
Prior art keywords
fluid
eye
preservative
keratoconjunctiva
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019541893A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532105A5 (enExample
Inventor
ゲオルグ コンラッド ミュラー−リアハイム、ウォルフガング
ゲオルグ コンラッド ミュラー−リアハイム、ウォルフガング
セッテン、ギースバート−ボソ ヴァン
セッテン、ギースバート−ボソ ヴァン
Original Assignee
アイ．コム メディカル ゲーエムベーハー
アイ．コム メディカル ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60766004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2019532105(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アイ．コム メディカル ゲーエムベーハー, アイ．コム メディカル ゲーエムベーハー filed Critical アイ．コム メディカル ゲーエムベーハー
Publication of JP2019532105A publication Critical patent/JP2019532105A/ja
Publication of JP2019532105A5 publication Critical patent/JP2019532105A5/ja
Priority to JP2022122165A priority Critical patent/JP2022153583A/ja
Priority to JP2024209810A priority patent/JP2025029084A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019541893A 2016-10-14 2017-10-02 角結膜のホメオスタシスを確立、回復及び維持するための方法 Pending JP2019532105A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022122165A JP2022153583A (ja) 2016-10-14 2022-07-29 角結膜のホメオスタシスを確立、回復及び維持するための方法
JP2024209810A JP2025029084A (ja) 2016-10-14 2024-12-02 角結膜のホメオスタシスを確立、回復及び維持するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662408559P 2016-10-14 2016-10-14
US62/408,559 2016-10-14
US201762516911P 2017-06-08 2017-06-08
US62/516,911 2017-06-08
PCT/IB2017/001364 WO2018069763A1 (en) 2016-10-14 2017-10-02 Method for establishing, restoring, and preserving homeostasis of the ocular surface

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022122165A Division JP2022153583A (ja) 2016-10-14 2022-07-29 角結膜のホメオスタシスを確立、回復及び維持するための方法
JP2024209810A Division JP2025029084A (ja) 2016-10-14 2024-12-02 角結膜のホメオスタシスを確立、回復及び維持するための方法

Publications (2)

Publication Number Publication Date
JP2019532105A true JP2019532105A (ja) 2019-11-07
JP2019532105A5 JP2019532105A5 (enExample) 2020-11-12

Family

ID=60766004

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019541893A Pending JP2019532105A (ja) 2016-10-14 2017-10-02 角結膜のホメオスタシスを確立、回復及び維持するための方法
JP2022122165A Pending JP2022153583A (ja) 2016-10-14 2022-07-29 角結膜のホメオスタシスを確立、回復及び維持するための方法
JP2024209810A Pending JP2025029084A (ja) 2016-10-14 2024-12-02 角結膜のホメオスタシスを確立、回復及び維持するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022122165A Pending JP2022153583A (ja) 2016-10-14 2022-07-29 角結膜のホメオスタシスを確立、回復及び維持するための方法
JP2024209810A Pending JP2025029084A (ja) 2016-10-14 2024-12-02 角結膜のホメオスタシスを確立、回復及び維持するための方法

Country Status (8)

Country Link
US (1) US20190240251A1 (enExample)
EP (2) EP3871682A1 (enExample)
JP (3) JP2019532105A (enExample)
KR (1) KR20190068575A (enExample)
ES (1) ES2909998T3 (enExample)
HU (1) HUE058672T2 (enExample)
PL (1) PL3525799T3 (enExample)
WO (1) WO2018069763A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023530286A (ja) * 2020-06-12 2023-07-14 アイ．コム メディカル ゲーエムベーハー 角膜神経損傷又は喪失の治療に使用する高分子量ヒアルロン酸

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190068575A (ko) 2016-10-14 2019-06-18 이콤 메디칼 게엠베하 안구 표면 항상성의 확립, 회복 및 보존 방법
WO2019202017A1 (en) * 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
CN112714644B (zh) * 2018-09-20 2024-03-29 香港科技大学 滴眼剂组合物
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
US20230233687A1 (en) * 2020-06-21 2023-07-27 i.com medical GmbH Hyaluronic acid-based formulations for treatment and prevention of ocular hypertension and glaucoma
EP4536189A1 (en) * 2022-06-08 2025-04-16 The Schepens Eye Research Institute, Inc. Methods for treating dry eye disease
EP4591860A1 (en) * 2024-01-23 2025-07-30 FB Vision S.p.A. Ophthalmic pharmaceutical composition for the prevention and treatment of dry eye syndrome

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6226225A (ja) * 1985-05-29 1987-02-04 アイ・リサ−チ・インステイテユ−ト・オブ・ザ・レテイナ・フアウンデイシヨン 無毒性眼科製剤
JPH0469342A (ja) * 1990-07-06 1992-03-04 Senju Pharmaceut Co Ltd 水性医薬製剤
JPH09216826A (ja) * 1995-12-22 1997-08-19 Chemedica Sa 眼外科用のヒアルロン酸ナトリウム主薬の眼製剤
JP2001316284A (ja) * 2000-04-07 2001-11-13 Lab Medidom Sa 眼科用製剤
JP2003160464A (ja) * 2001-11-28 2003-06-03 Denki Kagaku Kogyo Kk ヒアルロン酸及び／又はその塩の水溶液の安定化組成物
JP2004131489A (ja) * 1997-03-07 2004-04-30 Pharmacia Ab 眼用組成物
JP2004538096A (ja) * 2001-08-17 2004-12-24 ボシュ・アンド・ロム・インコーポレイテッド ヒドロゲルによるビグアニド抗菌剤の取り込みを阻害するための組成物および方法
JP2005513106A (ja) * 2001-12-12 2005-05-12 ウーアザファルマ アールツナイミッテル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント カンパニー カーゲー ヘパリンを保有する眼薬剤
JP2006502988A (ja) * 2002-07-03 2006-01-26 ペリコール・サイエンス・インコーポレーテッド ヒアルロン酸の組成物および使用方法
WO2008126803A1 (ja) * 2007-04-06 2008-10-23 Shiseido Company, Ltd. 可溶性架橋ヒアルロン酸含有眼用組成物
JP2009511423A (ja) * 2005-10-12 2009-03-19 生化学工業株式会社 粘膜適用剤及びその製造方法
WO2009139464A1 (ja) * 2008-05-15 2009-11-19 株式会社アールテック・ウエノ ドライアイおよび／または角結膜障害処置のための医薬組成物
JP2011093897A (ja) * 2009-09-30 2011-05-12 Rohto Pharmaceutical Co Ltd 眼科用液体組成物
JP2012077080A (ja) * 2010-09-10 2012-04-19 Santen Pharmaceut Co Ltd Ｐ２ｙ２受容体作動薬およびヒアルロン酸またはその塩を組み合わせたことを特徴とするドライアイ治療剤
JP2013518926A (ja) * 2010-02-09 2013-05-23 ボーシュ アンド ローム インコーポレイティド 無菌ヒアルロン酸溶液
WO2016143708A1 (ja) * 2015-03-06 2016-09-15 参天製薬株式会社 眼科用組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DE10360425A1 (de) 2003-12-19 2005-07-28 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Hyaluronsäure, Hyaluronat und/oder deren Derivate zur Herstellung einer pharmazeutischen Zusammensetzung
WO2009025763A2 (en) * 2007-08-16 2009-02-26 Schepens Eye Research Institute Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
DK2598526T3 (en) * 2010-07-29 2018-11-19 Eleven Biotherapeutics Inc CHEMICAL IL-1 RECEPTOR TYPE-I AGONISTS AND ANTAGONISTS
US20170360013A1 (en) * 2014-12-02 2017-12-21 Regeneron Pharmaceuticals, Inc. Animal model for dry eye and methods of use of such animals
US20170014339A1 (en) 2015-07-17 2017-01-19 i.com medical GmbH Tear Substitute, Fluid for Being Used as a Tear Substitute, and Method for Producing a Tear Substitute
KR20190068575A (ko) 2016-10-14 2019-06-18 이콤 메디칼 게엠베하 안구 표면 항상성의 확립, 회복 및 보존 방법
WO2019202017A1 (en) * 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
US12268706B2 (en) * 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6226225A (ja) * 1985-05-29 1987-02-04 アイ・リサ−チ・インステイテユ−ト・オブ・ザ・レテイナ・フアウンデイシヨン 無毒性眼科製剤
JPH0469342A (ja) * 1990-07-06 1992-03-04 Senju Pharmaceut Co Ltd 水性医薬製剤
JPH09216826A (ja) * 1995-12-22 1997-08-19 Chemedica Sa 眼外科用のヒアルロン酸ナトリウム主薬の眼製剤
JP2004131489A (ja) * 1997-03-07 2004-04-30 Pharmacia Ab 眼用組成物
JP2001316284A (ja) * 2000-04-07 2001-11-13 Lab Medidom Sa 眼科用製剤
JP2004538096A (ja) * 2001-08-17 2004-12-24 ボシュ・アンド・ロム・インコーポレイテッド ヒドロゲルによるビグアニド抗菌剤の取り込みを阻害するための組成物および方法
JP2003160464A (ja) * 2001-11-28 2003-06-03 Denki Kagaku Kogyo Kk ヒアルロン酸及び／又はその塩の水溶液の安定化組成物
JP2005513106A (ja) * 2001-12-12 2005-05-12 ウーアザファルマ アールツナイミッテル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント カンパニー カーゲー ヘパリンを保有する眼薬剤
JP2006502988A (ja) * 2002-07-03 2006-01-26 ペリコール・サイエンス・インコーポレーテッド ヒアルロン酸の組成物および使用方法
JP2009511423A (ja) * 2005-10-12 2009-03-19 生化学工業株式会社 粘膜適用剤及びその製造方法
WO2008126803A1 (ja) * 2007-04-06 2008-10-23 Shiseido Company, Ltd. 可溶性架橋ヒアルロン酸含有眼用組成物
WO2009139464A1 (ja) * 2008-05-15 2009-11-19 株式会社アールテック・ウエノ ドライアイおよび／または角結膜障害処置のための医薬組成物
JP2011093897A (ja) * 2009-09-30 2011-05-12 Rohto Pharmaceutical Co Ltd 眼科用液体組成物
JP2013518926A (ja) * 2010-02-09 2013-05-23 ボーシュ アンド ローム インコーポレイティド 無菌ヒアルロン酸溶液
JP2012077080A (ja) * 2010-09-10 2012-04-19 Santen Pharmaceut Co Ltd Ｐ２ｙ２受容体作動薬およびヒアルロン酸またはその塩を組み合わせたことを特徴とするドライアイ治療剤
WO2016143708A1 (ja) * 2015-03-06 2016-09-15 参天製薬株式会社 眼科用組成物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Double blind, randomised, placebo controlled, crossover, multicentre study to determine the efficacy", BRITISH JOURNAL OF OPHTALMOLOGY, vol. 83, JPN7021002779, 1999, pages 1121 - 1124, ISSN: 0004737212 *
"Tear substitutes Latest information on hyaluronic acid", AKTUELLE KONTAKTOLOGIE - CURRENT CONTACTOLOGY, vol. 11, JPN7021002781, 2015, pages 17 - 19, ISSN: 0004737210 *
"Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride", CHIESE MEDICAL JOURNAL, vol. 128(18), JPN7021002780, 2015, pages 2444 - 2449, ISSN: 0004737211 *
KRZOSKA: "EFFECTIVENESS OF COMFORT SHIELD MDS RESULTS OF A CLINICAL INVESTIGATION AT BEUTH HOCJSCHULE FUR TECK", GALIFA AUGENBLICK, JPN5020000398, July 2016 (2016-07-01), CH, pages 1 - 8, ISSN: 0004737209 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023530286A (ja) * 2020-06-12 2023-07-14 アイ．コム メディカル ゲーエムベーハー 角膜神経損傷又は喪失の治療に使用する高分子量ヒアルロン酸

Also Published As

Publication number Publication date
ES2909998T3 (es) 2022-05-11
KR20190068575A (ko) 2019-06-18
US20190240251A1 (en) 2019-08-08
EP3525799A1 (en) 2019-08-21
EP3525799B1 (en) 2022-01-26
HUE058672T2 (hu) 2022-09-28
WO2018069763A1 (en) 2018-04-19
JP2025029084A (ja) 2025-03-05
EP3871682A1 (en) 2021-09-01
JP2022153583A (ja) 2022-10-12
PL3525799T3 (pl) 2022-05-16

Similar Documents

Publication Publication Date Title
JP2019532105A (ja) 角結膜のホメオスタシスを確立、回復及び維持するための方法
AU2008289552B2 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
JP2025026942A (ja) 上皮の生存と体表面の再構成を高めるための高分子量ヒアルロン酸
US20250276004A1 (en) High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
EP3713530A1 (en) Ophthalmic composition and delivery device thereof
JP2023530189A (ja) 高眼圧症および緑内障の治療および予防のためのヒアルロン酸に基づく製剤
US12268706B2 (en) Hyaluronic acid for relief of idiopathic ocular pain
JP2023530286A (ja) 角膜神経損傷又は喪失の治療に使用する高分子量ヒアルロン酸
EA046057B1 (ru) Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности
AU2014227534B2 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
EA050162B1 (ru) Высокомолекулярная гиалуроновая кислота для улучшения выживания эпителия и восстановления поверхностей тела
CA2640986A1 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201001

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211026

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20211026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220329

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250428